Uploaded April 2021 | Updated September 2026, 14 hours ago
Arguing for establishment of a Health Impact Fund that would give pharmaceutical innovators the option to accept annual rewards based on the health impact of their new product in exchange for marketing it at cost of production and distribution. This Fund would spur additional R&D against diseases that impose large burdens mainly upon poor populations.
The presentation is followed by discussion with Dr. Gary Gottlieb (Harvard University and Partners in Health), Jami Taylor (Protagonist Therapeutics) and seminar participants.
This presentation and discussion took place at Yale University on 13 April 2021. Opinions and statements expressed by event moderators and participants are their own personal views and do not represent the views of the university.
Arguing for establishment of a Health Impact Fund that would give pharmaceutical innovators the option to accept annual rewards based on the health impact of their new product in exchange for marketing it at cost of production and distribution. This Fund would spur additional R&D against diseases that impose large burdens mainly upon poor populations.
The presentation is followed by discussion with Dr. Gary Gottlieb (Harvard University and Partners in Health), Jami Taylor (Protagonist Therapeutics) and seminar participants.
This presentation and discussion took place at Yale University on 13 April 2021. Opinions and statements expressed by event moderators and participants are their own personal views and do not represent the views of the university.
